Navigation Links
Home Dialysis Clinical Research Study is Underway - Focuses on At-Home Extended Duration Treatment

- Renal Solutions Announces Opportunity for Patients to Participate in

Research Aiming Toward Improved Future Dialysis Options -

WARRENDALE, Pa., Nov. 7 /PRNewswire/ -- Renal Solutions, Inc., the exclusive provider of advanced sorbent hemodialysis products and services, today announced that a home use clinical research trial has begun using sorbent technology. The study presents the opportunity for 25 dialysis study participants to evaluate the ability to self-administer extended duration dialysis in the home when using the Allient(R) Sorbent Hemodialysis System. In this study, the use of the Allient System in the home is an investigational use.

The Allient System enables hemodialysis using only 1.5 gallons (6 liters) of drinking water to provide a convenient therapy option requiring no plumbing modifications to a person's home. It is the only system that uses Sorbent Management for Advanced Renal Replacement Therapy (SMARRT(TM)). SMARRT therapy is based on more than 35 years of proven dialysis, using a gentle, patient-driven technology that enables flexible treatment options including extended duration dialysis therapy -- resulting in greater patient freedom and control.

"Our current participating clinical trial sites demonstrate their commitment to improving future patients' quality of life by taking part in a study like this," said David Vanella, Renal Solutions Vice President of Regulatory Affairs. "It's the drive to discover and apply new technologies that ultimately makes future alternative therapies available and accessible to patients."

The success of this trial may permit dialysis providers in the future to offer an alternative system and therapeutic modality to their patients. In the trial, study participants are trained and transitioned during the initial 8 weeks from self-care in a dialysis clinic setting to 8 weeks of dialysis self- administration in the home.

"Extended duration dialysis in the home is not a new concept and its potential benefits are well-known, including increased stamina, enhanced appetite and improved quality of life as just a few of the improvements this form of treatment can offer," said Renal Solutions CEO Peter M. DeComo. "The home modality has been out of vogue in part because available dialysis equipment hasn't been suited to the home. But it's on its way back. This trial may mark a tremendous step forward for people living with chronic kidney failure in the future."

"In addition to home hemodialysis being a proven alternative to in-center dialysis, at-home dialysis offers individuals more freedom and control in their lives," said Dr. Mark Rohrscheib, University of New Mexico Health Sciences Center. "The convenience of a dialysis technology that uses only a small amount of drinking water for each treatment is a tremendous advantage for home dialysis. Patients interested in new modalities will be excited to learn about this trial."

"We're pleased to be part of a trial that may introduce new options for our home dialysis patients," said Brigitte Schiller, MD, Director of Research, Satellite Healthcare, Mountain View, Ca. "This trial may further bring to light the benefits of extended duration dialysis."

Active recruitment has begun at multiple sites with subjects continuing to enroll in the study. Renal Solutions is working with a group of nephrologists and patient-focused dialysis facilities to conduct this trial. Individuals who are interested in contributing to a movement that is intended innovate the way chronic kidney failure is treated should ask their doctors about participating local research sites.

Patient-focused dialysis centers with certified home programs that are interested in learning more about this home trial should contact Mr. Vanella, (724) 772-6900, ext. 140.

About Renal Solutions, Inc.

Renal Solutions, Inc., a medical device and healthcare service company, is commercializing the Allient(R) Sorbent Hemodialysis System, a revolutionary technology/service solution for the chronic and acute dialysis market. The Allient System, brings SMARRT (Sorbent Management for Advanced Renal Replacement Therapy) therapy to the dialysis field, opening new treatment options to dialysis professionals and patients by virtue of its ability to provide short, standard or extended duration hemodialysis therapy using just 1 and 1/2 gallons of ordinary drinking water. Numerous clinical studies have shown that an increased cumulative dialysis dose results in better patient outcomes. The Allient System provides the increased dose advantage without the need for an independent water system or large volumes of sterile fluid. This translates into increased flexibility and convenience benefits.

SOURCE Renal Solutions, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Clinical trials present better alternatives for dialysis patients
2. Nighttime Home Dialysis a Boon for Kidney Patients
3. Nations Largest Dialysis Patient Organization Recognizes the Achievements of Patients and Leaders in Kidney Care
4. WellBound Teams With Kaiser Permanente to Open New Self-Care Dialysis Center in Sacramento, CA
5. New peritoneal dialysis diagnostic discovered
6. Early intervention dramatically improves outcomes for new dialysis patients
7. Dialysis Corporation of America Announces Third Quarter 2007 Earnings Release Date
8. Renal Solutions, Inc. Announces FDA 510(k) Clearance of New Design of the Allient(R) Sorbent Hemodialysis System for Chronic and Acute Hemodialysis
9. DaVita Emergency Response Efforts Ensure Vital Treatment for More than 700 Kidney Failure Patients in Need of Life-Saving Dialysis Treatments in Areas Affected by Southern California Wildfires
10. DaVita to Open First Independent Dialysis Clinic in Fargo-Moorhead
11. Radiologists encouraged to look beyond cancer for clinically unseen diseases
Post Your Comments:
(Date:11/27/2015)... ... , ... ProSidebar: Fashion is a set of 30 kinetic edge ... video editors can easily add an informative sidebar to any FCPX production. Create ... featuring self-animating drop zones, lines, bars, and text with the ease of FCPX's drag ...
(Date:11/27/2015)... ... ... A simply groundbreaking television series, "Voices in America", which is hosted by Hollywood ... issues that are presently affecting Americans. Dedicated to providing the world with a wide ... subjects consumers focus on, one episode at a time. , In the latest ...
(Date:11/27/2015)... IL (PRWEB) , ... November 27, 2015 , ... ... of the largest, most successful and prominent nonprofit healthcare organizations in the country. ... governance involvement with various organizations, and helped advance the healthcare industry as a ...
(Date:11/26/2015)... ... 26, 2015 , ... Patients at Serenity Point Recovery, a ... on Thanksgiving Day to share the things that they are most grateful for ... YouTube channel, patients displayed what they wrote on index cards, describing the things ...
(Date:11/26/2015)... ... ... The Catalent Applied Drug Delivery Institute today announced a ... selection in early phase drug development. The first of these is to be ... UK’s emerging life sciences companies, corporate partners, and investors, at Milton Park, Oxford, ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... 2015 --> ... online. The potential to save costs, improve treatment quality ... from fully exploited as yet. Here, particular emphasis is ... via mobile tablet or directly at the patients, bedside. ... ) -->      (Photo: ...
(Date:11/27/2015)... DUBLIN , Nov. 27, 2015 Research ... of the "Global Intrauterine Devices Market 2015-2019" ... --> In this report, the author ... intrauterine devices market for 2015-2019. To calculate the market ... of following type of products: Hormonal IUDs and copper ...
(Date:11/26/2015)... UTRECHT , Países Bajos, November 26, 2015 /PRNewswire/ ... con la terapia fotodinámica de Bremachlorin para el cáncer ... combina la inmunoterapia con la terapia fotodinámica de Bremachlorin ... Un nuevo enfoque combina la inmunoterapia con la ...   Clinical Cancer Research . --> ...
Breaking Medicine Technology: